SLNO_OUT_1 [2025-03-27 09:51:05 -0400] 2141 Bytes | 608 tokens | Cum: 608 tkns (7.60% of 8k)
==========================================================================

Listen up, partner—it's 9:51:03 AM on Thu Mar 27, 2025 -0400, and I’m revved up about Soleno Therapeutics (SLNO), climbing from 48.97 to 68.8557. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Soleno Therapeutics:

C1 - Mar-26-25 05:15PM - Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
C2 - Mar-26-25 05:15PM 01:15PM - First Prader-Willi drug to reduce hunger approved by FDA
C3 - Mar-21-25 09:20AM - Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
C4 - Feb-27-25 04:05PM - Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
C5 - Jan-29-25 04:05PM - Soleno Therapeutics to Participate in Upcoming February Investor Conferences
C6 - Jan-13-25 04:26PM - Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?
C7 - Dec-17-24 04:05PM - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
C8 - Nov-27-24 08:00AM - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Prior AI Reports for SLNO:

1. 2025-03-27 – Score: – – Target: – – Highs: – / – / –

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Soleno Therapeutics (SLNO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SLNO_OUT_3 [2025-03-27 09:51:11 -0400] 1099 Bytes | 350 tokens | Cum: 960 tkns (12.00% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome**
Date: Mar-26-25 05:15PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/26/3050184/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Approval-of-VYKAT-TM-XR-to-Treat-Hyperphagia-in-Prader-Willi-Syndrome.html

March 26, 2025 17:15 ET| Source:Soleno TherapeuticsSoleno Therapeutics

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome

Management to host conference call and webcast today, March 26th, at 5:30pm ET

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) exten

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SLNO_OUT_5 [2025-03-27 09:51:13 -0400] 985 Bytes | 301 tokens | Cum: 1334 tkns (16.68% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T13:30:13Z - Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Reta...
A2 - 2025-03-27T12:05:52Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Anebulo Pharmaceuticals (NASDAQ:ANEB...
A3 - 2025-03-27T12:24:55Z - Piper Sandler on Soleno Therapeutics Inc. (SLNO): 'VYKAT XR Approved With Spot Clean Label & Lucrati...
A4 - 2025-03-27T12:19:55Z - Why Is Soleno Therapeutics Soaring On Thursday? - Soleno Therapeutics (NASDAQ:SLNO)...
A5 - 2025-03-27T11:55:23Z - Stifel Reiterates Buy Rating on Soleno Therapeutics Inc. (SLNO)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SLNO_OUT_7 [2025-03-27 09:51:18 -0400] 1098 Bytes | 303 tokens | Cum: 1639 tkns (20.49% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks**Date: 2025-03-27Source: {'uri': 'newsable.asianetnews.com', 'dataType': 'news', 'title': 'Asianet News Network Pvt Ltd'}URL: https://newsable.asianetnews.com/markets/soleno-therapeutics-stock-rockets-34-pre-market-after-fda-approves-prader-willi-syndrome-drug-retail-sentiment-peaks-stsaudThe company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company received approval from the Food and Drug Administration (FDA) for its VYKAT XR extended-release tablets.

If the pre-market gains are sustained, the stock is headed toward its eight-year highs on a closing basis.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SLNO_OUT_9 [2025-03-27 09:51:20 -0400] 1089 Bytes | 315 tokens | Cum: 2051 tkns (25.64% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-21T18:00:00Z - Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight
B2 - 2024-11-27T13:00:00Z - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
B3 - 2024-07-20T02:42:23Z - Soleno Therapeutics enters agreement to sell $150 million in stock By Investing.com - Investing.com Canada
B4 - 2024-07-03T22:16:17Z - Soleno therapeutics exec sells over $90k in stock By Investing.com - Investing.com
B5 - 2024-07-03T22:16:17Z - Soleno therapeutics executive sells over $90k in stock By Investing.com - Investing.com
B6 - 2024-06-28T12:00:00Z - Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SLNO_OUT_11 [2025-03-27 09:51:26 -0400] 913 Bytes | 237 tokens | Cum: 2290 tkns (28.62% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/21/3030614/0/en/Evolving-Landscape-of-Obesity-Key-Market-Insights-of-Latest-Published-Different-Types-of-Obesity-DelveInsight.htmlThe obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SLNO_OUT_13 [2025-03-27 09:51:28 -0400] 1074 Bytes | 293 tokens | Cum: 2667 tkns (33.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-26 8-K ITEM2.02Results of Oper and Fin Conds

On March 26, 2025, Soleno Therapeutics, Inc. (the Company) issued a press release announcing that VYKAT TM XR (diazoxide choline) extended-release tablets has been approved by the U.S. Food and Drug Administration. VYKAT TM...

S2 - 2025-03-26 8-K ITEM2.02Results of Oper and Fin Conds

On March 26, 2025, Soleno Therapeutics, Inc. (the Company) issued a press release announcing that VYKAT TM XR (diazoxide choline) extended-release tablets has been approved by the U.S. Food and Drug Administration. VYKAT TM...

S3 - 2025-02-28 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis should be read in conjunction with our audited CONS financial statements and the related notes that appear elsewhere in this Annual Report...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SLNO_OUT_15 [2025-03-27 09:51:34 -0400] 971 Bytes | 260 tokens | Cum: 2929 tkns (36.61% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
ITEM2.02Results of Operations and Financial Conditions

On March 26, 2025, Soleno Therapeutics, Inc. (the Company) issued a press release announcing that VYKAT TM XR (diazoxide choline) extended-release tablets has been approved by the U.S. Food and Drug Administration. VYKAT TM XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM9.01Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description 99.1 Press release issued by Soleno Therapeutics, Inc. dated March 26, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)...

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SLNO_OUT_17 [2025-03-27 09:51:46 -0400] 5057 Bytes | 1476 tokens | Cum: 4502 tkns (56.27% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| Volume: 2,762,495 | SMA50: 44.34% | Market Cap: 3.21B | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| Avg Volume: 578.78K | SMA200: 43.41% | Shs Outstand: 45.70M | Short Float: 14.90% | Employees: 92 | EPS Surprise: -30.42% |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| Rel Volume: 76.76 | Perf Week: 44.52% | Shs Float: 33.47M | Short Ratio: 8.62 | Debt/Eq: 0.22 | P/E: - |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| RSI (14): 83.31 | Perf Month: 55.10% | Inst Own: 90.83% | Short Interest: 4.99M | Sales Y/Y TTM: - | Earnings: Feb 27 AMC |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| ATR (14): 3.77 | Perf Quarter: 55.63% | Insider Own: 27.00% | Beta: -2.09 | ROE: -87.35% | |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+
| SMA20: 43.86% | Index: RUT | Insider Trans: -0.58% | Sales Q/Q: - | ROI: -59.13% | |
+---------------------+----------------------+-----------------------+-------------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: SOLENO THERAPEUTICS INC (SLNO) by Anish Bhatnagar (CHIEF EXECUTIVE OFFICER) on 2025-01-21
- Common Stock: 53900 shares at $0 (D)
- Employee stock option (right to buy): 115600 shares at $0 (D)

Inside Trans: SOLENO THERAPEUTICS INC (SLNO) by Hirano Patricia C (SEE REMARKS) on 2025-01-21
- Common Stock: 6400 shares at $0 (D)
- Employee stock option (right to buy): 13800 shares at $0 (D)

Inside Trans: SOLENO THERAPEUTICS INC (SLNO) by Huang Michael F. (Sr. VP of Clinical Development) on 2025-01-21
- Common Stock: 6400 shares at $0 (D)
- Employee stock option (right to buy): 13800 shares at $0 (D)

Inside Trans: SOLENO THERAPEUTICS INC (SLNO) by Mackaness James H (CHIEF FINANCIAL OFFICER) on 2025-01-21
- Common Stock: 14500 shares at $0 (D)
- Employee stock option (right to buy): 31000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -175850000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 67.44
Average Volume: 927631.57
30-Day High: 67.44
30-Day Low: 43.68

[Detailed Financials: TTM 2024]
- Total Assets: $330,972,000.0
- Total Liabilities: $85,859,000.0
- Total Equity: $245,113,000.0
- Current Assets: $293,889,000.0
- Current Liabilities: $18,747,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-81,753,000.0

[Detailed Financials: FY 2024]
- Total Assets: $330,972,000.0
- Total Liabilities: $85,859,000.0
- Total Equity: $245,113,000.0
- Current Assets: $293,889,000.0
- Current Liabilities: $18,747,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-81,753,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SLNO_OUT_19 [2025-03-27 09:51:49 -0400] 676 Bytes | 167 tokens | Cum: 4886 tkns (61.08% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SLNO_IN_21 [2025-03-27 09:51:50 -0400] 126 Bytes | 29 tokens | Cum: 4943 tkns (61.79% of 8k)
==========================================================================

====================================
[2025-03-27 06:51:50] # Analysis Completed
Elapsed Time: 47.21 seconds